SCHEMBL25229097

SCHEMBL25229097

O=C(O)c1cc(Cl)ccc1Nc1c(N2CCOCC2)cnc2ccc(Cl)cc12

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.52
MEN1 O00255 2/20 0.52
GAA P10253 1/20 0.51
MAPT P10636 1/20 0.51
LMNA P02545 1/20 0.49
CSF1R P07333 2/20 0.44
KCNH2 Q12809 1/20 0.44
ALOX15 P16050 1/20 0.44
TSHR P16473 1/20 0.44
MAPK1 P28482 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
F10 P00742 1/20 0.42
PRKDC P78527 1/20 0.42
DHODH Q02127 1/20 0.41
IRAK4 Q9NWZ3 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
ALB P02768 1/20 0.41
SERPINE1 P05121 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25666211 0.93 KMT2A (0.48) KMT2AMEN1GAAMAPTLMNA
SCHEMBL25666210 0.93 GAA (0.52) KMT2AMEN1GAAMAPTLMNA
SCHEMBL25666121 0.93 KMT2A (0.46) KMT2AMEN1GAAMAPTLMNA
SCHEMBL25666146 0.93 KMT2A (0.46) KMT2AMEN1GAAMAPTLMNA
SCHEMBL25666212 0.91 MAPT (0.50) KMT2AMEN1GAAMAPTLMNA
SCHEMBL29266203 0.90 KMT2A (0.46) KMT2AMEN1GAAMAPTLMNA
SCHEMBL31386989 0.89 MAPT (0.56) KMT2AMEN1GAAMAPTLMNA
SCHEMBL25204377 0.89 MAPT (0.56) KMT2AMEN1GAAMAPTLMNA
SCHEMBL25211194 0.89 CSF1R (0.44) KMT2AMEN1GAAMAPTLMNA
SCHEMBL30351178 0.89 CSF1R (0.44) KMT2AMEN1GAAMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026769-A1 PAPD5 INHIBITORS AND METHODS OF USE THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2025-01-23 US disclosed
EP-4423081-A2 PAPD5 INHIBITORS AND METHODS OF USE THEREOF The Children's Medical Center Corporation (US) 2024-09-04 EP disclosed
CN-118201920-A PAPD5 inhibitors and methods of use thereof 儿童医疗中心公司 2024-06-14 CN disclosed
WO-2023086220-A2 PAPD5 INHIBITORS AND METHODS OF USE THEREOF THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2023-05-19 WO disclosed
WO-2023086220-A2 PAPD5 INHIBITORS AND METHODS OF USE THEREOF THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2023-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250026769-A1 PAPD5 INHIBITORS AND METHODS OF USE THEREOF POT1, PARP15, TERT KMT2A 2440/4885MEN1 3224/4885GAA 2562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.